TORONTO, Oct. 3 /CNW/ - Bradmer Pharmaceuticals Inc., a biopharmaceutical
company dedicated to the development and commercialization of cancer
therapies, today announced that it has appointed Zafeer Ahmad, Ph.D, to the
position of Vice President, Manufacturing Operations, and that it has accepted
the resignation of Kerry M. Barnhart, Ph.D, as President and Chief Scientific
Officer effective November 1, 2007. Chief Executive Officer Alan M. Ezrin,
Ph.D. will assume the additional role of President.
"Dr. Ahmad brings a wealth of knowledge in late-stage drug development.
As we prepare to submit our proposed multi-center Phase III trial protocol and
manufacturing data for Neuradiab to the FDA, Dr. Ahmad's experience in working
with contract research and contract manufacturing organizations will be
indispensable to Bradmer. Zafeer will also be a strong addition to our team as
we complete the validation and transfer of drug production from Duke
University to a commercial manufacturer," said Dr. Ezrin, Chief Executive
Officer of Bradmer. "Dr. Barnhart made a significant contribution to Bradmer
at an early stage and we wish him our best as he pursues other opportunities.
His decision to leave at this stage, after we've recruited a team with broad
experience in preparation for initiating the Phase III trial, will allow us to
make a seamless transition in the roles and responsibilities of the existing
Dr. Ahmad most recently held the position of Vice President, Process
Development and Manufacturing at NeoPharm, Inc. Prior to his work with
NeoPharm, Dr. Ahmad held senior positions at GlaxoSmithKline plc and
Hoffmann-La Roche Inc. He has more than 19 years of industry experience in
drug development, aseptic manufacturing operations, facility design and
validation, batch record and SOP preparation, outsourcing, tech transfer,
process validation and regulatory submission of drugs. Based on this
experience, Dr. Ahmad has a strong working knowledge of cGMP and CMC
documentation for IND and BLA preparation. From an academic perspective, Dr.
Ahmad held the position of Senior Scientist/Assistant Professor at Indiana
University, and was a Visiting Fellow at the National Institutes of Health in
Bethesda, MD. He received his Ph.D in Biochemistry from Aligarh University in
India. He has published numerous peer reviewed articles including nine papers
in the Journal of Biological Chemistry.
About Bradmer Pharmaceuticals Inc. (www.bradmerpharma.com)
Bradmer Pharmaceuticals is a biopharmaceutical company focused on the
development and commercialization of new and innovative cancer therapies.
Bradmer's lead clinical candidate, Neuradiab, was developed at Duke University
Medical Center as a proprietary therapy for a particularly aggressive form of
brain cancer, glioblastoma multiforme. To date, over US$60 million in grants
and related support has driven research and development of the licensed
treatment, which has been delivered to over 200 patients with promising
results and has completed Phase II clinical trials at Duke University. Bradmer
is currently in the process of organizing a prospective multi-center clinical
trial of the licensed treatment. Neuradiab has been granted Orphan Drug Status
by both the U.S. Food and Drug Administration and the European Medicines
Bradmer Pharmaceuticals Inc.'s common shares have not been registered
under the Securities Act of 1933, as amended (the "Securities Act") or any
state regulatory agency in the United States. The resale or transfer by a U.S.
investor of such common shares of Bradmer Pharmaceuticals Inc. is subject to
the requirements of Rule 904 of Regulation S of the Securities Act or such
other applicable exemption thereunder, and other applicable state securities
Except for historical information, this press release may contain
forward-looking statements, which reflect the Company's current expectation
regarding future events. These forward-looking statements involve risk and
uncertainties, which may cause but are not limited to, changing market
conditions, the successful and timely completion of clinical studies, the
establishment of corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the regulatory
approval process and other risks detailed from time to time in the Company's
ongoing quarterly and annual reporting.
For further information:
For further information: Bradmer Pharmaceuticals Inc., Mr. Brian
Brohman, Chief Business Officer, Phone: (416) 361-6058, (Ext. 804), E-mail:
email@example.com, Internet: www.bradmerpharma.com; Investor
Relations, Ross Marshall, The Equicom Group Inc., Phone: (416) 815-0700, (Ext.
238), Fax: (416) 815-0080, E-mail: firstname.lastname@example.org